Sysmex (OTCMKTS:SSMXY) Updates FY 2024 Earnings Guidance

Sysmex (OTCMKTS:SSMXY - Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.580-0.580 for the period. The company issued revenue guidance of $3.3 billion-$3.3 billion.

Sysmex Stock Performance

SSMXY traded down $0.18 during midday trading on Friday, hitting $17.90. 58,775 shares of the company traded hands, compared to its average volume of 84,987. The company has a quick ratio of 2.42, a current ratio of 3.19 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $11.27 billion, a PE ratio of 36.91 and a beta of 0.90. The company's 50-day moving average is $18.74 and its 200 day moving average is $19.02. Sysmex has a 52 week low of $14.38 and a 52 week high of $28.58.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter. On average, research analysts expect that Sysmex will post 0.57 EPS for the current year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.